Mark A. Mintun, MD has been the Vice-President of Pain and Neurodegeneration Research and Clinical Development since January of 2018 and Senior Vice-President of Neuroscience since October of 2021. In 2010, Dr. Mintun joined Avid Radiopharmaceuticals, a wholly-owned subsidiary of Eli Lilly & Co., as Chief Medical Officer and became its President in 2014. Prior to Avid, Dr. Mintun was Professor and Vice-Chair of Radiology at the Mallinckrodt Institute of Radiology at the Washington University School of Medicine, with joint appointments in Psychiatry, Neurology, Bioengineering, and the Anatomy and Neurobiology Departments. He earned a BS in Chemical Engineering from the Massachusetts Institute of Technology in 1977, received his medical degree in 1981 at Washington University School of Medicine and completed a research fellowship in neurology and residency training in nuclear medicine. Dr. Mintun has co-authored over 200 research publications that include reports of brain imaging to characterize flow/metabolism relationships, neurotransmitter systems, circuitry for processing affective stimuli and the pathology of neurodegenerative diseases. After joining Avid he led development programs for both amyloid and tau imaging of patients with neurodegenerative diseases. More recently he has overseen the extensive research and early phase development programs for Alzheimer disease, Parkinson disease, Migraine and Chronic Pain conditions.